COMMUNIQUÉS West-GlobeNewswire

Anavex Life Sciences Highlights Highly Qualified Board and Decisive Actions to Create Long-Term Value for Stockholders
11/08/2026
Files Definitive Proxy Statement and Mails Letter to Stockholders Urges Stockholders to Vote "FOR" All Six Anavex Director Nominees on the WHITE Proxy Card Underscores PVG’s Lack of Clear Plan and Inexperienced Slate of [...]
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
11/08/2026
Sentynl expands its rare disease portfolio with potential first-in-class oral treatment for AATD-LD, a rare genetic respiratory disease On option exercise, Sentynl will have the right to commercialize the product in the [...]
NovelMed Advances Its Ocular Program, Highlighting the Potential of a Single Therapy Across Multiple Retinal Diseases
11/08/2026
--- A Versatile Complement Therapy Across Ocular, Hematologic, Renal, Dermatological, and Inflammatory Disorders. Key Highlights Commercial Precedent for One Molecule, Two Diseases : Biogen’s $5.6 billion acquisition of [...]
Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
11/08/2026
Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026 The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high- [...]
Noah Medical Announces Galaxy™ II, the Next Dimension in Robotic-Assisted Bronchoscopy
11/08/2026
New functionality gives physicians the freedom to choose the right imaging for every case and a more responsive drive experience without adding capital, complexity, or radiation SAN JOSE, Calif., Aug. 11, 2026 (GLOBE [...]
Gibson Oncology Announces First Patient Completes Initial Treatment Cycle in Phase II Trial of LMP744 for Recurrent Glioblastoma
11/08/2026
Novel Blood-Brain-Barrier-Penetrant Agent Being Evaluated as a Single Therapy in a Trial Conducted by the National Institute of Neurological Disorders and Stroke (NINDS) MIAMI, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Gibson [...]
IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
11/08/2026
IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 [...]
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
11/08/2026
Two chrono-nutrition formulations — a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula — were developed in collaboration with the Taiwan CDHA and FHI. The Company intends to [...]
Neuronetics Reports Second Quarter 2026 Financial and Operating Results
11/08/2026
MALVERN, Pa., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient [...]
Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States
11/08/2026
TORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (TSX Venture: ARCH and OTCQB: ACHFF) today announced that the Company will expand its ongoing Phase II trial of LSALT peptide targeting cardiac surgery- [...]
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
11/08/2026
President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board of Directors [...]
Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
11/08/2026
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Secured equity [...]
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma
11/08/2026
Selected 0.60 mg/m 2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring Committee (DMC) following [...]
Constant Therapy Health Launches Web Platform for Speech, Language, and Cognitive Therapy
11/08/2026
Gives convenient desktop and laptop access to Constant Therapy’s clinically-proven rehabilitation exercise programs LEXINGTON, Mass., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Constant Therapy Health, a leader in AI-powered [...]
NeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue Growth
11/08/2026
Conference call will be held today, Tuesday, August 11 at 9:00 am ET CARMEL, Ind., Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
Boehringer Ingelheim expands equine health pipeline with acquisition of Evax AG
11/08/2026
Boehringer Ingelheim announced today that it has acquired Evax AG, a Swiss biotech company focused on equine health. Founded more than a decade ago at the University of Zurich, Evax has been exploring the use of [...]
Transactions in connection with share buy-back program
11/08/2026
Company announcement no. 30 - 26 11 August 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Exor and Philips Extend Long-term Relationship Agreement
11/08/2026
August 11, 2026 Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Exor N.V. today announced that they have agreed to update their long-term relationship [...]
Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed
11/08/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Tecan reports growth of 3.4% in local currencies and adjusted EBITDA margin of 15.1% for the first half of 2026, outlook confirmed [...]

Pages